Natalia B. Burmistrova

Natalia B. Burmistrova

Auto-generated profile, based on publicly available information

Natalia B. Burmistrova

City Clinical Hospital No. 52 of the Moscow Health Department

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2022 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
AZAlena I. Zagrebneva
Alena I. Zagrebneva
ESE. N. Simonova
E. N. Simonova
TMT. V. Mezenova
T. V. Mezenova
NBN. B. Burmistrova
N. B. Burmistrova
YGYu. A. Gavrikova
Yu. A. Gavrikova
ВДВ. В. Долгов
В. В. Долгов
Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.Patients and methods. A retrospective analysis of data from the register of patients with RA who during the COVID-19 pandemic were switched from foreign iIL6Rs to the Russian drug levilimab. Treatment regimens with levilimab in combination with synthetic diseasemodifying antirheumatic drugs (sDMARDs) and/or glucocorticoids (GCs) were used, as well as a monotherapy regimen in case of DMARDs intolerance.Results and discussion. In 150 patients with RA, a successful non-medical switch to levilimab was demonstrated with the preservation and intensification of the clinical effect achieved on previous therapy with iIL6R. After switching to levilimab, the DAS28-CRP index decreased by an average of 0.098 at 3 months and by 0.25 at 6 months (p=0.214 for both time points). There was a decrease in the proportion of patients with elevated levels of CRP, as well as with high RA activity. In a number of patients who showed high efficacy of levilimab, it became possible to reduce the dose or number of DMARDs, as well as cease GCs intake. Good tolerability and a favorable safety profile of levilimab were noted, including in relation to the new coronavirus infection that developed during therapy.Conclusion. Therapy with Russian iIL6R levilimab is effective and safe, including in patients switched from other drugs for non-medical reasons, as well as in relation to the novel coronavirus infection that developed during therapy.

20 January 2023 in HERALD of North-Western State Medical University named after I.I. Mechnikov
Verified
Journal Article
Closed access
PDF file
AZAlena I. Zagrebneva
Alena I. Zagrebneva
ESElena N. Simonova
Elena N. Simonova
ТMТatiana V. Mezenova
Тatiana V. Mezenova
NBNatalia B. Burmistrova
Natalia B. Burmistrova
YGYuliya A. Gavrikova
Yuliya A. Gavrikova
AFAnastasia A. Fomina
Anastasia A. Fomina
The growing demand for biological disease-modifying antirheumatic drugs (bDMARDs) and their high cost put a heavy burden on the healthcare budget, thereby limiting the availability of treatment for patients. The introduction of bDMARDs biosimilars into clinical practice has made it possible to expand the availability of therapy for a larger number of patients. Our analysis of the use of the biosimilar etanercept Erelzi in 103 patients with rheumatoid arthritis showed that the drug is highly effective in the treatment of rheumatoid arthritis. It can be used both in bionaive patients with the ineffectiveness of basic therapy, and in the case of medical switching from other biologics (including tumor necrosis factor alpha inhibitors (iTNF)) and targeted synthetic basic anti-inflammatory drugs (tsDMARDs), as well as when non-medical switching is necessary. The biosimilar of etanercept Erelzi has optimal cost of treatment course and the lowest cost-effectiveness value, which means that its use will not affect the budget and will make highly effective therapy available to more patients.